Semaglutide results week by week: what actually happens and when

What is actually happening in the first two weeks?

The opening fortnight is rarely about weight loss. It is about adjustment. Semaglutide works as a GLP-1 receptor agonist: it mimics a gut hormone that slows gastric emptying, reduces appetite signals sent to the brain, and raises feelings of fullness after eating. When those signals arrive for the first time, your body notices.

For many people the first thing they register is that a normal meal feels like too much. Portions that were routine become uncomfortable to finish. That shift in satiety can appear within days of the first injection. What it rarely produces in week one or two is a dramatic drop on the scales, and that is fine. The starting dose of 0.25 mg exists to let your system adapt, not to deliver the full therapeutic effect.

Side effects are most likely during this period. Nausea, loose stools, constipation and indigestion are the ones reported most often in trials and in clinical practice. They tend to peak in the first days after each new dose and then settle. Eating smaller portions, avoiding fatty or spicy food, and staying well hydrated helps most people get through it. If symptoms are severe or persistent, your prescriber needs to know.

You can read a closer look at what to expect from semaglutide after one week for a more granular picture of that earliest window.

When do most people start seeing measurable weight loss?

Weeks three to eight is typically when the scales begin to reflect what appetite changes have already set in motion. Eating less consistently (not through willpower but because hunger genuinely quietens) creates the calorie deficit that drives weight loss. For many people, this is the period where they start to believe it is working.

The dose is still escalating during this stretch: semaglutide is titrated roughly every four weeks by the prescriber, moving upward in steps toward the 2.4 mg maintenance level. Each increase can briefly revive nausea, which is normal and usually short-lived.

Clinical trial data from the STEP 1 study published in the New England Journal of Medicine tracked adults over 68 weeks and recorded an average loss of around 15% of body weight at 2.4 mg. That figure does not arrive at week four, it is the cumulative result of consistent treatment across more than a year. Early months typically account for a meaningful share of the total, but the curve is not linear and individual experience varies considerably.

There is an understandable temptation, especially if friends or family are losing weight faster, to feel that something is wrong. It usually is not. Factors including starting body weight, metabolic rate, how closely the titration schedule is followed, and changes to diet and activity all influence the pace. For a closer look at this phase, see semaglutide results at four weeks and what tends to change by week eight.

What does the longer arc look like beyond the first couple of months?

From around months three to six, most people reach their maintenance dose or approach it. This is where the numbers in clinical trials accumulate most visibly. Weight loss continues, though the rate often slows as the body adapts and as appetite recalibrates at a new baseline.

The STEP 1 trial's 15% average is the benchmark that NICE referenced when recommending semaglutide for weight management under TA875. That recommendation also specifies that if fewer than 5% of body weight has been lost after six months on the maintenance dose, continuing treatment should be reviewed with a clinician. That threshold is a clinical prompt, not a verdict, it is there to make sure treatment is genuinely helping.

Beyond six months, weight loss typically plateaus or slows. Some people continue to see gradual reductions; others stabilise. NICE's current guidance for semaglutide recommends a maximum treatment duration of two years within a specialist framework on the NHS. For people receiving private treatment, duration is an ongoing clinical conversation. The full Wegovy week-by-week results guide covers the longer timeline in more detail.

One thing worth saying plainly: if you are a few weeks in and feeling frustrated because progress feels slower than you expected, that is an extremely common and understandable place to be. The clinical data shows that the biggest changes in body weight accumulate over months, not days. Staying consistent with the prescribed dose, the dose schedule, and any lifestyle support your prescriber recommends is the part you can control.

Does the higher 7.2 mg dose change the timeline?

In January 2026 the MHRA approved a 7.2 mg dose of semaglutide (Wegovy), and a dedicated single-dose pen for it was approved in April 2026. Trial data at that dose reported average weight loss of around 20.7% over 72 weeks, closer to the results seen with tirzepatide at higher doses. The titration pathway to 7.2 mg starts the same way, at 0.25 mg, and the prescriber-led escalation schedule remains the same. Nothing about the week-by-week pattern is fundamentally different; the endpoint shifts, not the journey. Specific dose availability is confirmed during the clinical consultation, not before.

If you are weighing up how the injection and tablet forms of semaglutide compare, or how Wegovy compares with other licensed treatments, our Wegovy treatment page covers both. Details on how long the medicine typically takes to produce noticeable effects are also covered on the dedicated page about how long Wegovy takes to work.

Semaglutide is a prescription-only medicine. Every person who starts treatment through nume has their consultation reviewed on the same day by a GPhC-registered prescriber (a real clinician reading your answers) and clinical suitability is assessed before anything is approved. If you would like to find out whether Wegovy is right for you, speak to our prescribers through a free consultation.